Dual Site-Specific Antibody Conjugates for Sequential and Orthogonal Cargo Release

Bioconjug Chem. 2019 Jun 19;30(6):1702-1710. doi: 10.1021/acs.bioconjchem.9b00244. Epub 2019 May 24.


Antibody-drug conjugates utilize the antigen specificity of antibodies and the potency of chemotherapeutic and antibiotic drugs for targeted therapy. However, as cancers and bacteria evolve to resist the action of drugs, innovative controlled release methods must be engineered to deliver multidrug cocktails. In this work, we engineer lipoate-acid ligase A (LplA) acceptor peptide (LAP) tags into the constant heavy and light chain of a humanized Her2 targeted antibody, trastuzumab. These engineered LAP tags, along with the glutamine 295 (Q295) residue in the heavy chain, were used to generate orthogonally cleavable site-specific antibody conjugates via a one-pot chemoenzymatic ligation with microbial transglutaminase (mTG) and LplA. We demonstrate orthogonal cargo release from these dual-labeled antibody bioconjugates via matrix metalloproteinase-2 and cathepsin-B-mediated bond cleavage. To the best of our knowledge, this is the first demonstration of temporal control on dual-labeled antibody conjugates, and we believe this platform will allow for sequential release and cooperative drug combinations on a single antibody bioconjugate.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents, Immunological / chemistry*
  • Antineoplastic Agents, Immunological / pharmacokinetics
  • Cell Line, Tumor
  • Drug Liberation
  • Humans
  • Immunoconjugates / chemistry*
  • Immunoconjugates / pharmacokinetics
  • Models, Molecular
  • Peptide Synthases / chemistry
  • Peptides / chemistry
  • Trastuzumab / chemistry*
  • Trastuzumab / pharmacokinetics


  • Antineoplastic Agents, Immunological
  • Immunoconjugates
  • Peptides
  • Peptide Synthases
  • lipoate-protein ligase
  • Trastuzumab